Using Wegovy for small weight loss: what the trial data really says

The STEP 1 trial averages hide a wide spread of individual results

The headline figure from the STEP 1 trial (approximately 15% average body-weight reduction over 68 weeks) comes from a large, rigorous study published in the New England Journal of Medicine. Averages, by definition, sit in the middle of a distribution. Some participants lost considerably more; others lost significantly less. A substantial number of people in the trial lost 5–10% of their starting weight and still reported clinically meaningful improvements in blood pressure, blood sugar and joint pain. That matters, because the benefit from modest weight loss is real and measurable well before anyone reaches the trial average.

If your goal is to lose one or two stone rather than a larger amount, you are not necessarily outside the range of what this medicine can support, and our Wegovy weight loss page sets out in detail what the evidence says about how that support works in practice. What the data does not tell us is how any individual will respond, that depends on starting weight, how the body tolerates each dose step, diet, activity, and other health factors. A prescriber reviewing your case can give you a more grounded sense of what reasonable expectations look like for your situation.

It is also worth noting that the NICE appraisal of semaglutide (Wegovy) references stopping treatment if less than 5% weight loss is achieved after six months at the maintenance dose, per NICE technology appraisal TA875. That threshold is a clinical review point, not a verdict on whether treatment was worthwhile, and it underlines that ongoing use is always a prescriber decision.

Why small targets can still meet the eligibility bar

The Wegovy licence in the UK is not written around a weight-loss target; it is written around a starting BMI and health profile. Adults with a BMI of 30 or above, or 27 or above alongside a qualifying condition such as high blood pressure, high cholesterol, type 2 diabetes, prediabetes or obstructive sleep apnoea, may be eligible for assessment. Lower BMI thresholds can apply for certain ethnic backgrounds under UK guidance.

Someone who wants to lose a relatively small amount of weight might still have a BMI in the licensed range, with health conditions that make even a modest reduction clinically worthwhile. Conversely, someone with a small weight-loss goal but a low BMI and no comorbidities would not meet the licensed criteria, however reasonable their goal sounds. The eligibility question and the weight-loss goal question are separate, and conflating them is one of the more common sources of confusion people bring to a consultation.

If you are unsure where you sit, the NHS BMI calculator gives you an accurate starting point before you speak to a prescriber.

How Wegovy's mechanism shapes the experience of a smaller loss

Wegovy activates GLP-1 receptors in the gut and brain, slowing gastric emptying and reducing appetite signals. The result for most people is that hunger becomes less insistent, meals feel satisfying with less food, and the pull towards snacking is reduced. That physiological shift is the same whether your goal is five kilos or twenty. You are not relying on motivation alone to eat less; the medicine is doing some of that work at a hormonal level.

For someone aiming at a modest loss, this mechanism means the treatment may feel proportionate once the dose is established, with the hardest period usually being the early weeks of titration when GI side effects (nausea, loose stools, reduced appetite) tend to be most noticeable. These typically ease as the body adjusts. You can read more about the practical experience of taking Wegovy for a clearer picture of what those first months look like.

For men specifically, appetite physiology and starting weight can influence how quickly results appear, there is more on this at our Wegovy for men page.

Cost, commitment and whether Wegovy is the right fit for a modest goal

If you are considering Wegovy for a smaller weight-loss target, it is worth being honest about the commitment involved. This is a weekly injection taken over many months, with a titration schedule that builds gradually, and a private cost that varies by dose and provider. For some people, the clinical and lifestyle benefits justify that investment even for a modest goal; for others, a conversation about whether this is the right tool is the most useful place to start.

You feel this question for a reason. It is a reasonable thing to wonder whether a medicine developed for significant obesity is proportionate when your goal is more limited. The honest answer is that it depends entirely on your health profile, your BMI, and what a prescriber concludes after reviewing you properly. No article (including this one) can answer that for you.

At nume, every consultation is read by a GPhC-registered prescriber on the day it arrives. There is no subscription, no auto-renewal, and no obligation after the consultation if treatment is not appropriate. If you would like a clinical view on whether Wegovy fits your situation, you can speak to our prescribers through a free consultation.